Brief: Ascentage Pharma Says Olverembatinib Approved For Commercialization In Macau China
08/07/2024 01:55
July 7 (Reuters) - Ascentage Pharma Group International
6855.HK :
* OLVEREMBATINIB APPROVED FOR COMMERCIALIZATION IN MACAU
CHINA
Source text for Eikon: ID:nPnbv9ZCa
Further company coverage: 6855.HK
((Reuters.briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up